<DOC>
	<DOC>NCT00685906</DOC>
	<brief_summary>The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.</brief_summary>
	<brief_title>AZD6140 Oral Contraceptive Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Females who are healthy, nonpregnant, not planning pregnancy within the study period, nonbreastfeeding, and premenopausal Either currently taking Nordette® which was well tolerated for at least two months prior to randomisation with no history of breakthrough bleeding, or, willing to take Nordette for 2 months prior to receiving the study drug Females of childbearing potential must be willing to use at least 1 additional medically approved nonhormonal barrier contraceptive method (for example, condom or diaphragm) that contains spermicide History of intolerance (e.g. adverse events) to any oral contraceptive or AZD6140 History of blood vessel or bleeding conditions that would make the volunteer more prone to bleeding History or presence of significant medical problems Women who are current smokers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>oral contraceptive</keyword>
	<keyword>birth control</keyword>
	<keyword>Healthy volunteers</keyword>
</DOC>